Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announces the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025. The UniverXome subsidiary was established prior to Serina’s reverse merger with AgeX Therapeutics in March 2024 to own the legacy assets of the predecessor company.
Read the full article: Serina Therapeutics Announces Sale of UniverXome Subsidiary //
Source: https://www.globenewswire.com/news-release/2025/01/15/3010432/0/en/Serina-Therapeutics-Announces-Sale-of-UniverXome-Subsidiary.html